@article{fbd344abd44f4de68c83e6f06d6d6974,
title = "Expanded Indications for Neoadjuvant Endocrine Therapy in Early-Stage Breast Cancer During the COVID-19 Pandemic",
keywords = "Breast cancer, Chemotherapy, Endocrine therapy, Neoadjuvant, Pandemic, Surgery delay, Prognosis, Pandemics, Breast Neoplasms/pathology, Humans, Middle Aged, Receptors, Estrogen/metabolism, SARS-CoV-2, COVID-19/epidemiology, Mastectomy, Female, Neoadjuvant Therapy, Adult, Triage, Antineoplastic Agents, Hormonal/therapeutic use, Receptor, ErbB-2/metabolism, Time-to-Treatment/statistics \& numerical data, Practice Guidelines as Topic/standards, Receptors, Progesterone/metabolism, Aged, Neoplasm Staging",
author = "Rhami Khorfan and Vora, \{Halley P.\} and Namm, \{Jukes P.\} and Solomon, \{Naveenraj L.\} and Lum, \{Sharon S.\}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",
year = "2024",
month = oct,
doi = "10.1245/s10434-024-15787-8",
language = "English",
volume = "31",
pages = "7562--7568",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
number = "11",
}